Nature Communications (Feb 2023)
11β-HSD1 inhibition in men mitigates prednisolone-induced adverse effects in a proof-of-concept randomised double-blind placebo-controlled trial
- Nantia Othonos,
- Riccardo Pofi,
- Anastasia Arvaniti,
- Sarah White,
- Ilaria Bonaventura,
- Nikolaos Nikolaou,
- Ahmad Moolla,
- Thomas Marjot,
- Roland H. Stimson,
- André P. van Beek,
- Martijn van Faassen,
- Andrea M. Isidori,
- Elizabeth Bateman,
- Ross Sadler,
- Fredrik Karpe,
- Paul M. Stewart,
- Craig Webster,
- Joanne Duffy,
- Richard Eastell,
- Fatma Gossiel,
- Thomas Cornfield,
- Leanne Hodson,
- K. Jane Escott,
- Andrew Whittaker,
- Ufuk Kirik,
- Ruth L. Coleman,
- Charles A. B. Scott,
- Joanne E. Milton,
- Olorunsola Agbaje,
- Rury R. Holman,
- Jeremy W. Tomlinson
Affiliations
- Nantia Othonos
- Oxford Centre for Diabetes, Endocrinology and Metabolism, NIHR Oxford Biomedical Research Centre, University of Oxford, Churchill Hospital
- Riccardo Pofi
- Oxford Centre for Diabetes, Endocrinology and Metabolism, NIHR Oxford Biomedical Research Centre, University of Oxford, Churchill Hospital
- Anastasia Arvaniti
- Oxford Centre for Diabetes, Endocrinology and Metabolism, NIHR Oxford Biomedical Research Centre, University of Oxford, Churchill Hospital
- Sarah White
- Oxford Centre for Diabetes, Endocrinology and Metabolism, NIHR Oxford Biomedical Research Centre, University of Oxford, Churchill Hospital
- Ilaria Bonaventura
- Oxford Centre for Diabetes, Endocrinology and Metabolism, NIHR Oxford Biomedical Research Centre, University of Oxford, Churchill Hospital
- Nikolaos Nikolaou
- Oxford Centre for Diabetes, Endocrinology and Metabolism, NIHR Oxford Biomedical Research Centre, University of Oxford, Churchill Hospital
- Ahmad Moolla
- Oxford Centre for Diabetes, Endocrinology and Metabolism, NIHR Oxford Biomedical Research Centre, University of Oxford, Churchill Hospital
- Thomas Marjot
- Oxford Centre for Diabetes, Endocrinology and Metabolism, NIHR Oxford Biomedical Research Centre, University of Oxford, Churchill Hospital
- Roland H. Stimson
- University/BHF Centre for Cardiovascular Science, University of Edinburgh
- André P. van Beek
- Department of Endocrinology, University of Groningen, University Medical Center Groningen
- Martijn van Faassen
- Department of Laboratory Medicine, University of Groningen, University Medical Center Groningen
- Andrea M. Isidori
- Department of Experimental Medicine, Sapienza University of Rome
- Elizabeth Bateman
- Department of Immunology, Churchill Hospital
- Ross Sadler
- Department of Immunology, Churchill Hospital
- Fredrik Karpe
- Oxford Centre for Diabetes, Endocrinology and Metabolism, NIHR Oxford Biomedical Research Centre, University of Oxford, Churchill Hospital
- Paul M. Stewart
- Faculty of Medicine & Health, University of Leeds
- Craig Webster
- Department of Pathology, University Hospitals Birmingham, NHS Foundation Trust
- Joanne Duffy
- Department of Pathology, University Hospitals Birmingham, NHS Foundation Trust
- Richard Eastell
- Mellanby Centre for Musculoskeletal Research, Department of Oncology & Metabolism, Faculty of Medicine, Dentistry & Health, University of Sheffield
- Fatma Gossiel
- Mellanby Centre for Musculoskeletal Research, Department of Oncology & Metabolism, Faculty of Medicine, Dentistry & Health, University of Sheffield
- Thomas Cornfield
- Oxford Centre for Diabetes, Endocrinology and Metabolism, NIHR Oxford Biomedical Research Centre, University of Oxford, Churchill Hospital
- Leanne Hodson
- Oxford Centre for Diabetes, Endocrinology and Metabolism, NIHR Oxford Biomedical Research Centre, University of Oxford, Churchill Hospital
- K. Jane Escott
- Business Development & Licensing, BioPharmaceuticals R&D, AstraZeneca
- Andrew Whittaker
- Emerging Innovations Unit, Discovery Sciences, BioPharmaceuticals R&D, AstraZeneca
- Ufuk Kirik
- Quantitative Biology, Discovery Sciences, BioPharmaceuticals R&D AstraZeneca
- Ruth L. Coleman
- Oxford Centre for Diabetes, Endocrinology and Metabolism, NIHR Oxford Biomedical Research Centre, University of Oxford, Churchill Hospital
- Charles A. B. Scott
- Oxford Centre for Diabetes, Endocrinology and Metabolism, NIHR Oxford Biomedical Research Centre, University of Oxford, Churchill Hospital
- Joanne E. Milton
- Oxford Centre for Diabetes, Endocrinology and Metabolism, NIHR Oxford Biomedical Research Centre, University of Oxford, Churchill Hospital
- Olorunsola Agbaje
- Oxford Centre for Diabetes, Endocrinology and Metabolism, NIHR Oxford Biomedical Research Centre, University of Oxford, Churchill Hospital
- Rury R. Holman
- Oxford Centre for Diabetes, Endocrinology and Metabolism, NIHR Oxford Biomedical Research Centre, University of Oxford, Churchill Hospital
- Jeremy W. Tomlinson
- Oxford Centre for Diabetes, Endocrinology and Metabolism, NIHR Oxford Biomedical Research Centre, University of Oxford, Churchill Hospital
- DOI
- https://doi.org/10.1038/s41467-023-36541-w
- Journal volume & issue
-
Vol. 14,
no. 1
pp. 1 – 12
Abstract
Glucocorticoids prescribed to limit inflammation, have significant adverse effects. Here the authors show that co-administration of AZD4017 with prednisolone in men is a potential strategy to limit adverse glucocorticoid effects.
